Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug combination consists of the local anesthetic lidocaine and the synthetic glucocorticoid dexamethasone, investigated by Assiut University as an adjuvant therapy for intravenous regional anesthesia (IVRA), also known as a Bier block. Lidocaine acts by blocking voltage-gated sodium channels to inhibit nerve conduction, while dexamethasone is added to enhance the duration of sensory and motor blockade and provide extended postoperative analgesia. This specific combination is primarily utilized in patients undergoing forearm orthopedic surgeries to improve anesthetic efficacy, reduce tourniquet pain, and decrease the requirement for postoperative opioids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + dexamethasone.